| Home: Info: News Releases: 2004 Archives: February 11, 2004 |
| Press Release February 11, 2004 | |
LAKE FOREST, Calif., Feb 11, 2004 (BUSINESS WIRE) -- I-Flow Corporation (Nasdaq:IFLO) announced today that it will address institutional shareholders at The 16th Annual Roth Capital Partners Growth Stock Conference on Tuesday, February 17, 2004 at 8:30 a.m. PT at the St. Regis Monarch Beach Resort & Spa, Dana Point, California. You can access the live Webcast of this 30-minute presentation, after registration, from the Investors link or the Investors Event Calendar link at www.IFLO.com. The Webcast will be available for replay on February 17, 2004 after 11:00 a.m. PT at this same address for twelve months. Audio streams require Windows Media installation. I-Flow Corporation is an emerging leader in post-surgical pain relief. The Company's ON-Q(R) PainBuster(R) Post-Op Pain Relief System provides targeted pain relief after surgery only where the body needs it, delivering a non-narcotic, pain-numbing medication directly to an incision site for up to five days. The anesthetic is administered through a specially-designed catheter inserted by a surgeon during surgery. ON-Q PainBuster is cleared for use by the U.S. Food & Drug Administration (FDA). About I-Flow I-Flow Corporation (www.iflo.com) designs, develops and markets technically advanced drug delivery systems that are redefining the standard of care by providing life-enhancing, cost-effective solutions for pain relief. Certain disclosures made by the Company in this press release and in other reports and statements released by the Company are and will be forward-looking in nature, such as comments that express the Company's opinions about trends and factors which may impact future operating results. Disclosures that use words such as the Company "believes," "anticipates," or "expects" or use similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, which could cause actual results to differ from those expected, and readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to republish revised forward-looking statements to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures made by the Company in this report which seek to advise interested parties of the risks and other factors that affect the Company's business, as well as in the Company's periodic reports on Forms 10-K, 10-Q, and 8-K filed with the Securities and Exchange Commission. The risks affecting the Company's business include reliance on the success of the home health care industry, the reimbursement system currently in place and future changes to that system, competition in the industry, economic conditions in foreign countries, currency exchange rates, technological changes, product availability and the Company's efforts to rapidly build a substantial direct sales force. Any such forward-looking statements, whether made in this report or elsewhere, should be considered in context with the various disclosures made by the Company about its business. SOURCE: I-Flow Corporation I-Flow Corporation
James R. Talevich, 949-206-2700
www.iflo.com
or
Berkman Associates
John Hicks, 310-277-5162 (Investors)
info@BerkmanAssociates.com
Customize your Business Wire news & multimedia to match your needs. Get breaking news from companies and organizations worldwide. Logon for FREE today at www.BusinessWire.com. |
JOBS
| NEWS
| SITEMAP | SALES INFOCENTER HEALTHCARE COMPLIANCE PROGRAM | HIPAA PRIVACY NOTICE © 2004-2010 I-FLOW CORPORATION. All Rights Reserved There are inherent risks in all medical devices, please refer to the product labeling for Indications, Cautions, Warnings and Contraindications.For example, failure to follow the product labeling regarding filling, flow rate selection and placement of the pump and/or catheter could directly impact patient safety. Physician is responsible for prescribing and administering medications per instructions provided by the drug manufacturer. |